Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH4C3M)

Drug Name
STA-5326 Drug Info
Synonyms Apilimod; STA 5326; STA5326; N-[(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [1]
Cross-matching ID
PubChem CID
10173277
CAS Number
CAS 541550-19-0
TTD Drug ID
DMH4C3M

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Interleukin-12 alpha (IL12A)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ustekinumab DMHTYK3 Plaque psoriasis EA90.0 Approved [3]
Mirikizumab DM7R3N5 Ulcerative colitis DD71 Approved [4]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-12 alpha (IL12A) TTRTK6Y IL12A_HUMAN Inhibitor [2]

References

1 A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis. 2006 Jul;12(7):558-65.
2 Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis. Arthritis Res Ther. 2008;10(5):R122.
3 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)